An advocacy group asked the Department of Health and Human Services to investigate whether a key hepatitis C patent held by Gilead Sciences (GILD) failed to disclose federal funding for grants that were used to develop the blockbuster Sovaldi treatment.

In making its request, the advocacy group cited a federal database purportedly showing a patent awarded to Pharmasset, which developed Sovaldi, had received funding from the National Institutes of Health for four grants. The grants were provided between 2003 and 2006, and the patent was issued in June 2011, a few months before Gilead bought Pharmasset for $11 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy